Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Income from Continuing Operations of 74111000.0 for Q1 2026, down 33.92% year-over-year from 112156551.78 in Q1 2025, and down 379.99% quarter-over-quarter from 15440000.0 in Q4 2025.
Powered by 
Analysis
Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Income from Continuing Operations for 5 consecutive years, with 74111000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 33.92% year-over-year to 74111000.0; the TTM figure through Mar 2026 stood at 220668000.0 (down 7.73% YoY), while the FY2025 annual figure was 201896000.0, down 11.18% from the prior year.
- Income from Continuing Operations eased to 74111000.0 in Q1 2026 per APGE's latest filing, from 15440000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1816000.0 in Q2 2022 and bottomed at 74111000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 37886125.0 across 5 years, with a median of 32955000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 939.92% — and 2025, when it jumped 76.84%.
- Apogee Therapeutics' Income from Continuing Operations stood at 20782000.0 in 2022, then sank by 197.92% to 61913000.0 in 2023, then decreased by 7.66% to 66658000.0 in 2024, then surged by 76.84% to 15440000.0 in 2025, then plunged by 379.99% to 74111000.0 in 2026.
- Business Quant data shows APGE's Income from Continuing Operations at 74111000.0 in Q1 2026, 15440000.0 in Q4 2025, and 65021000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Apogee Therapeutics | 10.18 Bn | 9.20 Bn | - | -85.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -85.85 Mn |
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -15.44 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -28.95 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | -31.74 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.10 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |